UY34647A - Composiciones farmacéuticas - Google Patents

Composiciones farmacéuticas

Info

Publication number
UY34647A
UY34647A UY0001034647A UY34647A UY34647A UY 34647 A UY34647 A UY 34647A UY 0001034647 A UY0001034647 A UY 0001034647A UY 34647 A UY34647 A UY 34647A UY 34647 A UY34647 A UY 34647A
Authority
UY
Uruguay
Prior art keywords
pharmaceutical compositions
indazol
yloxy
pyrazol
tolyl
Prior art date
Application number
UY0001034647A
Other languages
English (en)
Inventor
Alisha B Arrigo
Donald T Corson
Coralee G Mannila
Original Assignee
Array Biopharma Inc Una Soc Organizada Conforme A Las Leyes Del Estado De Delaware Eeuu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47891993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY34647(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc Una Soc Organizada Conforme A Las Leyes Del Estado De Delaware Eeuu filed Critical Array Biopharma Inc Una Soc Organizada Conforme A Las Leyes Del Estado De Delaware Eeuu
Publication of UY34647A publication Critical patent/UY34647A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

En la presente se proporciona una sal de cloruro de hidrógeno de 1-(3-terc-butil-1-p-tolil-1H-pirazol-5-il)-3-(5-fluoro-2-(1-(2-hidroxietil)-1H-indazol-5-iloxi)bencil)urea, formas cristalinas de clorhidrato de 1-(3-terc-butil-1-p-5 tolil-1H-pirazol-5-il)-3-(5-fluoro-2-(1-(2-hidroxietil)-1H-indazol-5-iloxi)bencil)urea, procesos para la preparación de dichas formas cristalinas, composiciones farmacéuticas que contienen una forma cristalina de la Forma B de clorhidrato de 1-(3-terc-butil-1-p-tolil-1H-pirazol-5-il)-3-(5-fluoro-2-10 (1-(2-hidroxietil)-1H-indazol-5-iloxi)bencil)urea, procesos para la preparación de dichas composiciones, composiciones farmacéuticas preparadas mediante dichos métodos y el uso de dichas composiciones en el tratamiento de varias enfermedades y trastornos.
UY0001034647A 2012-03-01 2013-02-28 Composiciones farmacéuticas UY34647A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261605572P 2012-03-01 2012-03-01

Publications (1)

Publication Number Publication Date
UY34647A true UY34647A (es) 2014-09-30

Family

ID=47891993

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034647A UY34647A (es) 2012-03-01 2013-02-28 Composiciones farmacéuticas

Country Status (28)

Country Link
US (1) US9278936B2 (es)
EP (2) EP2819998B1 (es)
JP (2) JP6177809B2 (es)
KR (2) KR102298597B1 (es)
CN (1) CN104245677B (es)
AR (1) AR090209A1 (es)
AU (1) AU2013226163B2 (es)
CA (1) CA2865808C (es)
CL (1) CL2014002296A1 (es)
CO (1) CO7071134A2 (es)
CR (1) CR20140408A (es)
DK (1) DK2819998T3 (es)
ES (1) ES2919923T3 (es)
HK (1) HK1204475A1 (es)
IL (1) IL234192B (es)
MX (1) MX355734B (es)
MY (1) MY183153A (es)
NZ (1) NZ630033A (es)
PH (1) PH12014501834A1 (es)
PL (1) PL2819998T3 (es)
PT (1) PT2819998T (es)
RU (1) RU2627702C2 (es)
SG (1) SG11201405357SA (es)
SI (1) SI2819998T1 (es)
TW (1) TWI610673B (es)
UA (1) UA113302C2 (es)
UY (1) UY34647A (es)
WO (1) WO2013130573A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9969747B2 (en) 2014-06-20 2018-05-15 Constellation Pharmaceuticals, Inc. Crystalline forms of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl)acetamide
CA3128468A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2023084459A1 (en) 2021-11-15 2023-05-19 Pfizer Inc. Methods of treating sars-cov-2
CN117198527B (zh) * 2023-08-24 2024-02-23 北京大学人民医院 一种亲缘造血干细胞移植术后的风险评估系统及方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596306B1 (en) 2000-07-07 2003-07-22 David Ho Sue San Ho Drug delivery system:formulation for fat-soluble drugs
JP2002249426A (ja) * 2000-12-22 2002-09-06 Takeda Chem Ind Ltd 経口医薬組成物
FR2818905A1 (fr) 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
US20030191093A1 (en) * 2001-12-03 2003-10-09 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
JP4617299B2 (ja) * 2003-03-03 2011-01-19 アレイ バイオファーマ、インコーポレイテッド ｐ３８阻害剤及びその使用法
AU2004270733B2 (en) * 2003-09-11 2011-05-19 Itherx Pharma, Inc. Cytokine inhibitors
JP5131990B2 (ja) * 2006-01-31 2013-01-30 アレイ バイオファーマ、インコーポレイテッド キナーゼ阻害剤およびその使用方法

Also Published As

Publication number Publication date
NZ630033A (en) 2016-09-30
PT2819998T (pt) 2022-05-05
CL2014002296A1 (es) 2014-11-07
EP2819998B1 (en) 2022-04-06
JP6177809B2 (ja) 2017-08-09
CA2865808A1 (en) 2013-09-06
RU2014139607A (ru) 2016-04-20
TW201336494A (zh) 2013-09-16
MX2014010538A (es) 2015-03-09
SI2819998T1 (sl) 2022-07-29
PH12014501834B1 (en) 2014-11-10
MX355734B (es) 2018-04-27
DK2819998T3 (da) 2022-04-19
SG11201405357SA (en) 2014-10-30
MY183153A (en) 2021-02-16
IL234192A0 (en) 2014-11-02
CA2865808C (en) 2020-07-14
CN104245677A (zh) 2014-12-24
ES2919923T3 (es) 2022-07-29
KR102477065B1 (ko) 2022-12-13
TWI610673B (zh) 2018-01-11
WO2013130573A1 (en) 2013-09-06
IL234192B (en) 2019-11-28
JP2017128591A (ja) 2017-07-27
US9278936B2 (en) 2016-03-08
CO7071134A2 (es) 2014-09-30
AU2013226163B2 (en) 2017-06-08
KR20210113410A (ko) 2021-09-15
KR20140138233A (ko) 2014-12-03
AR090209A1 (es) 2014-10-29
EP2819998A1 (en) 2015-01-07
KR102298597B1 (ko) 2021-09-06
AU2013226163A1 (en) 2014-09-25
HK1204475A1 (en) 2015-11-20
JP2015508820A (ja) 2015-03-23
EP4101844A1 (en) 2022-12-14
CN104245677B (zh) 2017-05-10
US20150030673A1 (en) 2015-01-29
RU2627702C2 (ru) 2017-08-10
CR20140408A (es) 2014-10-14
UA113302C2 (xx) 2017-01-10
PL2819998T3 (pl) 2022-06-27
PH12014501834A1 (en) 2014-11-10

Similar Documents

Publication Publication Date Title
CL2017001249A1 (es) Forma cristalina de sulfato de hidrógeno (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidinaa-1-il)-pirazolo[1,5-a] pirimidinaa-3-il)-3-hidroxipirrolidinaa-1-carboxamida.
CO2018013585A2 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para uso en el tratamiento de transtornos neurodegenerativos.
DOP2016000250A (es) Una forma amorfa y una cristalina de hemitartrato genz 112638 como inhibidor de glucosilceramida sintasa
PH12014501277A1 (en) Kinase inhibitors
CR20150114A (es) Composición farmacéutica recubierta que contiene regorafenib
LT2688885T (lt) N-(1,3,4-oksadiazol-2-il)arilkarboksamidai ir jų panaudojimas kaip herbicidų
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
EA201600506A1 (ru) КРИСТАЛЛИЧЕСКИЙ КОМПЛЕКС 1-ЦИАНО-2-(4-ЦИКЛОПРОПИЛБЕНЗИЛ)-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)БЕНЗОЛА, СПОСОБЫ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
GT201400183A (es) Inhibidores de cinasa de fosfoinositida 3 cristalina
PH12014501278A1 (en) Kinase inhibitors
MX2014008020A (es) Compuestos de fenil carbamato para uso en la prevencion o tratamiento de epilepsia.
UY34647A (es) Composiciones farmacéuticas
CL2008002809A1 (es) Compuestos derivados de cianoisoquinolina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una adiccion a las drogas, en el tratamiento de un trastorno neurodegenerativo, como alzheimer, parkinson, demencia, entre otros.
AR086586A1 (es) Forma cristalina de ciclosporina a, metodos de preparacion y metodos para utilizar la misma
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
BRPI0606199A2 (pt) hidrocloreto de rimonabant, processo para a preparação de um hidrocloreto de rimonabant, composição farmacêutica, forma de dosagem farmacêutica, uso de um hidrocloreto de rimonabant e método de tratamento
BR112016017776A8 (pt) forma cristalina ou forma sólida de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidróxi-4-metil-ciclo-hexilamino)-pirimidina-5-carboxamida, método de preparo, método de purificação, composto, composição farmacêutica e uso de forma cristalina ou forma sólida
MX2013008197A (es) Sales de aminas organicas de azilsartan, metodo de preparacion y uso de las mismas.
CO6592109A2 (es) Nueva forma cristalina de un derivado de ciclopropilbenzamida
CL2015001940A1 (es) Formulación que comprende un compuesto de benzotiazolona.
AR080203A1 (es) Formas solidas que comprenden una ciclopropilamida
CO6680604A2 (es) Forma cristalina de un compuesto 3-fenocimetilpirrolidina
EA201301021A1 (ru) Применение пригодной для распыления композиции, содержащей амброксол
CY1118132T1 (el) ΣΤΕΡΕΕΣ ΜΟΡΦΕΣ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ (1R,4R)-6'-ΦΘΟΡΟ-Ν,Ν-ΔΙΜΕΘΥΛ-4-ΦΑΙΝΥΛ-4',9'-ΔΙΥΔΡΟ-3´H-ΣΠΕΙΡΟ-[ΚΥΚΛΟΕΞΑΝΟ-1,1'-ΠΥΡΑΝΟ[3,4,b]ΙΝΔΟΛ]-4-ΑΜΙΝΗΣ
TH156839A (th) รูปแบบที่เป็นผลึกของ 1-(3-เทอร์ท-บิวทิล-1-พี-โทลิล-1เอช-ไพราซอล-5-อิล)-3-(5-ฟลูออโร-2-(1-(2-ไฮดรอกซีเอทิล)-1เอช-อินดาซอล-5-อิลอกซี)เบนซิล)ยูเรียไฮโดรคลอไรด์